Azacitidine's Mechanism in GVHD Treatment
Azacitidine treats graft-versus-host disease (GVHD) primarily by acting as a hypomethylating agent that incorporates into DNA and RNA, altering gene expression to reduce inflammation and immune overactivity post-transplant.[1]
How Azacitidine Modifies DNA
Azacitidine is a cytidine nucleoside analog. After cellular uptake and conversion to azacitidine triphosphate, it integrates into newly synthesized DNA during the S-phase of the cell cycle. This traps DNA methyltransferase (DNMT) enzymes, progressively depleting them and causing DNA hypomethylation. In GVHD, this demethylates promoters of immune-regulatory genes (e.g., FOXP3 in T-regulatory cells), boosting their expression to suppress donor T-cell alloreactivity against host tissues.[2][3]
How Azacitidine Modifies RNA
Azacitidine also incorporates into RNA as a fraudulent nucleotide, disrupting RNA metabolism, maturation, and protein synthesis. It inhibits RNA synthesis and polyribosome formation, which curbs proliferation of hyperactive alloreactive T-cells and reduces pro-inflammatory cytokine production (e.g., TNF-alpha, IL-6) driving GVHD pathology.[1][4]
Specific Role in GVHD
In acute and chronic GVHD, azacitidine shifts T-cell profiles toward tolerance: it expands regulatory T-cells (Tregs), reduces Th1/Th17 effector cells, and dampens antigen-presenting cell function. Clinical data show response rates of 30-60% in steroid-refractory cases, with hypomethylation correlating to lower tissue damage in skin, gut, and liver.[3][5]
Differences from Decitabine
Unlike decitabine (also a hypomethylating agent), azacitidine affects both DNA and RNA due to its stability in plasma and dual incorporation. Decitabine is DNA-specific and loses efficacy faster outside S-phase, making azacitidine better for GVHD's heterogeneous immune cells.[2]
Clinical Evidence and Risks
Trials (e.g., phase II studies) report GVHD improvement via epigenetic reprogramming, with overall survival benefits in high-risk post-transplant settings.[5] Common risks include cytopenias (myelosuppression from DNA/RNA disruption), nausea, and infection; monitoring methylation status predicts response.[1]
Sources
[1]: FDA Label for Vidaza (azacitidine)
[2]: Hypomethylating Agents in GVHD, Blood Advances (2020)
[3]: Azacitidine for Steroid-Refractory GVHD, Biol Blood Marrow Transplant (2018)
[4]: RNA Incorporation Effects, Cancer Research (1978)
[5]: Meta-Analysis of HMAs in GVHD, Front Immunol (2022)